This article was originally published in The Gray Sheet
Executive SummaryPrivate placement raises $13 mil. to support marketing of the San Diego firm's AutoDose multi-chamber infusion system. The device was 510(k) cleared in February 2000. The privately held company will use a portion of the proceeds to expand sales and marketing initiatives and increase manufacturing capacity
You may also be interested in...
Reforms to the US 180-day exclusivity incentive included in the Blocking Act that is part of the Lower Health Care Costs Act could cost the US healthcare system approximately $1.7bn, the AAM has warned.
Moderate growth at Bristol-Myers Squibb and Amgen moved the two companies into the top 10 pharma ranks, based on the most recent Scrip 100 rankings, while declining growth at Gilead and Teva moved those drug makers out.